The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

This was the stock's second consecutive day of gains.

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Retirement Systems of Alabama made a bold financial move by increasing its stake in Regeneron Pharmaceuticals by a whopping ...